Can Celgene and bluebird bio Survive a Two-Pronged Attack?

Around this time last year, investors were thrilled with bluebird bio (NASDAQ: BLUE), and a next-generation cancer therapy that the pre-commercial biotech is developing in partnership with Celgene (NASDAQ: CELG). The partners recently presented encouraging clinical trial results, but they're not the only ones trying to help a limited population of advanced-stage multiple myeloma patients.